ATE552276T1 - Modifizierter anti-cd52-antikörper - Google Patents
Modifizierter anti-cd52-antikörperInfo
- Publication number
- ATE552276T1 ATE552276T1 AT04817412T AT04817412T ATE552276T1 AT E552276 T1 ATE552276 T1 AT E552276T1 AT 04817412 T AT04817412 T AT 04817412T AT 04817412 T AT04817412 T AT 04817412T AT E552276 T1 ATE552276 T1 AT E552276T1
- Authority
- AT
- Austria
- Prior art keywords
- antibody
- modified anti
- antibodies
- expected
- potential
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/467—Igs with modifications in the FR-residues only
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51621003P | 2003-11-01 | 2003-11-01 | |
| PCT/IB2004/003879 WO2005042581A2 (en) | 2003-11-01 | 2004-10-29 | Modified anti-cd52 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE552276T1 true ATE552276T1 (de) | 2012-04-15 |
Family
ID=34549504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04817412T ATE552276T1 (de) | 2003-11-01 | 2004-10-29 | Modifizierter anti-cd52-antikörper |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US7264806B2 (de) |
| EP (1) | EP1694706B1 (de) |
| JP (1) | JP4804357B2 (de) |
| CN (1) | CN1898267B (de) |
| AT (1) | ATE552276T1 (de) |
| BR (1) | BRPI0416141B8 (de) |
| CA (1) | CA2544365A1 (de) |
| DK (1) | DK1694706T3 (de) |
| ES (1) | ES2384105T3 (de) |
| PT (1) | PT1694706E (de) |
| WO (1) | WO2005042581A2 (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100056762A1 (en) * | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| AU2011202920C1 (en) * | 2006-05-30 | 2012-11-15 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
| US9498528B2 (en) | 2006-09-13 | 2016-11-22 | Genzyme Corporation | Treatment of multiple sclerosis (MS) |
| CA2691539C (en) * | 2007-06-21 | 2014-08-26 | Angelica Therapeutics, Inc. | Modified toxins |
| EP2268297A4 (de) * | 2008-02-29 | 2011-11-16 | Angelica Therapeutics Inc | Modifizierte toxine |
| WO2010110838A2 (en) * | 2009-03-25 | 2010-09-30 | Vet Therapeutics Inc. | Antibody constant domain regions and uses thereof |
| EP2429583A4 (de) | 2009-05-13 | 2013-10-16 | Genzyme Corp | Verfahren und zusammensetzungen zur lupus-behandlung |
| BRPI1013085A2 (pt) | 2009-05-13 | 2020-11-03 | Genzyme Corporation | imunoglobulinas anti-cd52 humana |
| GB0914691D0 (en) * | 2009-08-21 | 2009-09-30 | Lonza Biologics Plc | Immunoglobulin variants |
| CA2791866A1 (en) * | 2010-03-04 | 2011-09-09 | Vet Therapeutics, Inc. | Monoclonal antibodies directed to cd52 |
| US9616120B2 (en) * | 2010-03-04 | 2017-04-11 | Vet Therapeutics, Inc. | Monoclonal antibodies directed to CD20 |
| WO2012068540A2 (en) | 2010-11-19 | 2012-05-24 | Toshio Imai | Neutralizing anti-ccl20 antibodies |
| EP3263125A3 (de) | 2011-02-02 | 2018-03-14 | Emory University | Antagonismus des vip-signalweges |
| GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| EP2952210A3 (de) | 2011-04-07 | 2016-03-16 | Emory University | Zusammensetzungen mit saccharidbindenden teilen und verfahren zur gezielten therapie |
| GB201109238D0 (en) * | 2011-06-01 | 2011-07-13 | Antitope Ltd | Antibodies |
| WO2013059885A2 (en) | 2011-10-28 | 2013-05-02 | Cephalon Australia Pty Ltd | Polypeptide constructs and uses thereof |
| CN105518018B (zh) * | 2013-03-15 | 2020-04-03 | 细胞基因公司 | 修饰的t淋巴细胞 |
| AR095199A1 (es) | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
| US10059750B2 (en) | 2013-03-15 | 2018-08-28 | Angelica Therapeutics, Inc. | Modified toxins |
| JP6433085B2 (ja) | 2013-04-09 | 2018-12-05 | ボストン バイオメディカル， インコーポレイテッド | がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン |
| KR20170071485A (ko) | 2014-10-14 | 2017-06-23 | 폴리테릭스 리미티드 | Peg의 일부를 포함하는 이탈기를 포함하는 시약을 사용한, 펩티드 또는 단백질의 접합방법 |
| AU2016271475A1 (en) | 2015-06-03 | 2017-12-21 | Boston Biomedical, Inc. | Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer |
| CA3045306A1 (en) | 2016-11-29 | 2018-06-07 | Boston Biomedical, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
| US20200071417A1 (en) | 2017-04-19 | 2020-03-05 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| WO2018213424A1 (en) | 2017-05-17 | 2018-11-22 | Boston Biomedical, Inc. | Methods for treating cancer |
| US20200377571A1 (en) | 2017-12-08 | 2020-12-03 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| WO2019209952A2 (en) | 2018-04-23 | 2019-10-31 | Emory University | Vip antagonists and uses in treating cancer |
| WO2020069372A1 (en) | 2018-09-27 | 2020-04-02 | Elstar Therapeutics, Inc. | Csf1r/ccr2 multispecific antibodies |
| US20230365709A1 (en) | 2020-10-08 | 2023-11-16 | Affimed Gmbh | Trispecific binders |
| AU2022320948A1 (en) | 2021-07-30 | 2024-01-18 | Affimed Gmbh | Duplexbodies |
| CA3233696A1 (en) | 2021-11-03 | 2023-05-11 | Joachim Koch | Bispecific cd16a binders |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548640B1 (en) * | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5846534A (en) * | 1988-02-12 | 1998-12-08 | British Technology Group Limited | Antibodies to the antigen campath-1 |
| WO1989009622A1 (en) | 1988-04-15 | 1989-10-19 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
| SG88714A1 (en) | 1989-11-06 | 2002-05-21 | Cell Genesys Inc | Production of proteins using homologous recombination |
| EP0438310A1 (de) | 1990-01-19 | 1991-07-24 | Merck & Co. Inc. | Verfahren zur Herstellung von rekombinanten Immunoglobulinen |
| GB9014932D0 (en) * | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| CU22615A1 (es) * | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
| US5846543A (en) | 1995-10-24 | 1998-12-08 | Hassler; Mark A. | Bovine mastitis treatment |
| AU736549B2 (en) * | 1997-05-21 | 2001-08-02 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Method for the production of non-immunogenic proteins |
| GB9712892D0 (en) | 1997-06-20 | 1997-08-20 | Eclagen Ltd | Identification of mhc binding peptides |
| US6835550B1 (en) * | 1998-04-15 | 2004-12-28 | Genencor International, Inc. | Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins |
| CN1202128C (zh) | 1998-12-08 | 2005-05-18 | 拜奥威神有限公司 | 修饰蛋白的免疫原性 |
| EP1324771B2 (de) * | 2000-10-09 | 2018-06-06 | CytomX Therapeutics, Inc. | Therapeutische und toleranz-induzierende Antikörper |
| KR100899970B1 (ko) * | 2001-02-19 | 2009-05-28 | 메르크 파텐트 게엠베하 | Ｔ-세포 에피토프의 동정 방법 및 감소된 면역원성을 갖는분자의 제조를 위한 용도 |
| EP1448602B1 (de) * | 2001-11-12 | 2010-05-26 | MERCK PATENT GmbH | Modifizierter anti-tnf antikörper |
| US20030157641A1 (en) * | 2001-11-16 | 2003-08-21 | Idec Pharmaceuticals Corporation | Polycistronic expression of antibodies |
-
2004
- 2004-10-29 EP EP04817412A patent/EP1694706B1/de active Active
- 2004-10-29 PT PT04817412T patent/PT1694706E/pt unknown
- 2004-10-29 BR BRPI0416141A patent/BRPI0416141B8/pt active IP Right Grant
- 2004-10-29 DK DK04817412.2T patent/DK1694706T3/da active
- 2004-10-29 JP JP2006537487A patent/JP4804357B2/ja not_active Expired - Fee Related
- 2004-10-29 CA CA002544365A patent/CA2544365A1/en not_active Abandoned
- 2004-10-29 ES ES04817412T patent/ES2384105T3/es active Active
- 2004-10-29 CN CN200480036043XA patent/CN1898267B/zh active Active
- 2004-10-29 US US10/977,369 patent/US7264806B2/en active Active
- 2004-10-29 AT AT04817412T patent/ATE552276T1/de active
- 2004-10-29 WO PCT/IB2004/003879 patent/WO2005042581A2/en active Application Filing
-
2007
- 2007-08-03 US US11/833,818 patent/US7910104B2/en active Active
- 2007-10-31 US US11/932,086 patent/US20080248529A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP4804357B2 (ja) | 2011-11-02 |
| CN1898267A (zh) | 2007-01-17 |
| BRPI0416141B8 (pt) | 2021-05-25 |
| CA2544365A1 (en) | 2005-05-12 |
| US7264806B2 (en) | 2007-09-04 |
| DK1694706T3 (da) | 2012-07-16 |
| US7910104B2 (en) | 2011-03-22 |
| EP1694706B1 (de) | 2012-04-04 |
| WO2005042581A2 (en) | 2005-05-12 |
| US20080075715A1 (en) | 2008-03-27 |
| WO2005042581A8 (en) | 2006-06-29 |
| BRPI0416141A (pt) | 2007-01-02 |
| WO2005042581A3 (en) | 2005-07-28 |
| PT1694706E (pt) | 2012-06-19 |
| BRPI0416141B1 (pt) | 2019-01-15 |
| US20050152898A1 (en) | 2005-07-14 |
| JP2007534304A (ja) | 2007-11-29 |
| ES2384105T3 (es) | 2012-06-29 |
| US20080248529A1 (en) | 2008-10-09 |
| CN1898267B (zh) | 2012-05-23 |
| EP1694706A2 (de) | 2006-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE552276T1 (de) | Modifizierter anti-cd52-antikörper | |
| CY1121208T1 (el) | Σκευασματα αντισωματος ναταλιζουμαμπης | |
| CY1116632T1 (el) | Εξουδετερωτες αντισωματων του τελεστη διεγερσης αποικιων κοκκιοκυτταρων μακροφαγων ανθρωπου | |
| TW200745161A (en) | Stable antibody formulation | |
| DE602006006200D1 (de) | Antikörper gegen 25-hydroxyvitamin d | |
| TR201901841T4 (tr) | Her antikorlarının sabit dozlaması. | |
| CY1118343T1 (el) | Αντισωματα συνδεσης twεακ | |
| PE20140806A1 (es) | Anticuerpos anti-factor d humanizados y sus usos | |
| MA30153B1 (fr) | Anticorps anti-ox40l et methodes correspondantes | |
| IL244803B (en) | Human anti-beta antibodies and their use | |
| UA92505C2 (ru) | Композиции на основе антитела против cd3 | |
| BRPI0314814C1 (pt) | anticorpo compreendendo uma variante de fc | |
| EA200802170A1 (ru) | Лиофилизированная композиция терапевтического пептидного антитела | |
| GT200500298A (es) | Formulaciones de anticuerpos | |
| CR10530A (es) | Anticuerpos anti-dlla4 y metodos que los usan | |
| ATE475672T1 (de) | Anti-il-23-antikörper | |
| NO20083895L (no) | Anti-IGF-1R human monoklonalantibody formulering | |
| BR122018016045B8 (pt) | proteína variante otimizada | |
| TW200714290A (en) | Anti-M-CSF antibody compositions having reduced levels of endotoxin | |
| MA35009B1 (fr) | Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci | |
| CR10555A (es) | Vacunas para malaria | |
| UA94211C2 (ru) | Выделенное полностью человеческое моноклональное cd3 антитело | |
| NO20084320L (no) | Antistoffer mot EGFL7 og fremgangsmater for anvendelse av disse | |
| EA200800601A1 (ru) | Связывающие fas антитела | |
| GT201300058A (es) | Composiciones de anticuerpos anti-vegfr-3 |